3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
117
Squamous Cell Carcinoma of Head and Neck
61
Triple Negative Breast Neoplasms
55
Melanoma
54
Lung Neoplasms
49
Neoplasm Metastasis
47
Breast Neoplasms
42
Neoplasms
38
Colorectal Neoplasms
37
Head and Neck Neoplasms
26
Endometrial Neoplasms
25
Carcinoma, Renal Cell
25
Ovarian Neoplasms
22
Uterine Cervical Neoplasms
21
Stomach Neoplasms
21
Carcinoma, Transitional Cell
21
Urinary Bladder Neoplasms
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
19
Recurrence
16
Esophageal Neoplasms
16
Pancreatic Neoplasms
15
Carcinoma, Hepatocellular
14
Sarcoma
12
Glioblastoma
12
Carcinoma, Squamous Cell
12
Prostatic Neoplasms
11
Esophageal Squamous Cell Carcinoma
11
Carcinoma
11
Brain Neoplasms
10
Carcinoma, Merkel Cell
9
Interventions
Carboplatin
4
pertuzumab
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Paclitaxel
2
Oxaliplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
talazoparib
1
sarilumab
1
relugolix
1
regorafenib
1
pexidartinib
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
nimotuzumab
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pathologic Complete Response
×
pembrolizumab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled